Emyria has opened a new facility – The Empax Centre – and expanded its clinical service capacity to deliver and develop new treatments for mental health including MDMA-assisted therapy (MDMA-AT) for PTSD.
Led by some of Australia’s first authorised MDMA-AT prescribers, Emyria said the Empax Centre is aiming to achieve operational profitability by H2 2024 with the potential for national and global scalability via further site expansion.
It will initially target critical gaps in care for resistant PTSD, with a strategy to expand therapeutic offerings using the same foundational infrastructure.
